GO
| HSI1 | 24,856.43 | -479.52 | 261.66B |
| HSCEI1 | 8,389.93 | -192.81 | 116.50B |
| Back Zoom + Zoom - Block Traded | |
|
2026-03-26 10:45:23 CSPC PHARMA (01093.HK)'s 2025 revenue and net profit dropped by 10% YoY to RMB26 billion and RMB3.9 billion, respective, according to a report from Citi. The company also recorded a YoY fall of 25% in sales expenses to RMB6.5 billion and an increase of 12% in R&D costs to RMB5.8 billion. The management maintains a conservative outlook, though it expects the FY26 results to turn positive. Citi has reduced its target price for CSPC PHARMA from HKD12.1 to HKD11.5 but kept the Buy rating unchanged. ~ AAStocks Financial News Web Site: www.aastocks.com | |